Suppr超能文献

2017 年至 2023 年中国江苏省水痘疫苗接种后不良事件监测。

Surveillance of adverse events following varicella vaccine immunization in Jiangsu province, China from 2017 to 2023.

机构信息

Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.

Jiangsu Health Development Research Center, Nanjing, China.

出版信息

BMC Infect Dis. 2024 Sep 16;24(1):983. doi: 10.1186/s12879-024-09903-y.

Abstract

UNLABELLED

To assess the safety of varicella vaccine (VarV) by conducting post-marketing surveillance on adverse events following immunization (AEFI) in Jiangsu Province, China.

METHODS

We utilized the AEFI Information System of mainland China to monitor and categorize adverse reactions associated with VarV.

RESULTS

The incidence rate of AEFI was significantly higher after the first dose (48.79/100,000 doses) compared to the second dose (45.18/100,000 doses) (χ = 4.63, P = 0.031). Regional variations in AEFI incidence were observed within Jiangsu Province. Common reactions comprised 90.96% of AEFIs, while rare reactions and coincidental events accounted for 6.59% and 0.51%, respectively. Notably, there were no adverse events linked to vaccine quality, program errors, psychogenic reactions, or fatalities. Over 96% of AEFIs occurred within three days of VarV administration, with redness at the injection site (2.6 cm to 5 cm in diameter) being the most frequently observed symptom.

CONCLUSION

VarV demonstrates a commendable safety profile. Although there was a slight increase in AEFI incidence between 2022 and 2023, common vaccine reactions were predominantly observed, and the rates of rare reactions remained very low.

摘要

目的

通过对江苏省疫苗接种后不良反应(AEFI)进行上市后监测,评估水痘疫苗(VarV)的安全性。

方法

利用中国大陆 AEFI 信息系统对 VarV 相关不良反应进行监测和分类。

结果

与第二剂(45.18/100000 剂)相比,第一剂 VarV 的 AEFI 发生率明显更高(48.79/100000 剂)(χ=4.63,P=0.031)。江苏省内存在 AEFI 发生率的区域差异。常见反应占 AEFIs 的 90.96%,罕见反应和偶合事件分别占 6.59%和 0.51%。值得注意的是,没有与疫苗质量、计划错误、精神反应或死亡相关的不良事件。超过 96%的 AEFIs发生在 VarV 给药后 3 天内,注射部位发红(直径 2.6-5cm)是最常见的症状。

结论

VarV 具有良好的安全性。尽管 2022 年至 2023 年之间 AEFI 发生率略有增加,但主要观察到常见疫苗反应,罕见反应发生率仍非常低。

相似文献

3
Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review.疫苗接种后乙肝疫苗不良事件报告:13 年回顾。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2411824. doi: 10.1080/21645515.2024.2411824. Epub 2024 Oct 13.

本文引用的文献

8
Comparison of varicella outbreaks in schools in China during different vaccination periods.不同疫苗接种时期中国校内水痘暴发疫情比较。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2114255. doi: 10.1080/21645515.2022.2114255. Epub 2022 Aug 22.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验